High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines
Open Access
- 1 November 1992
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 66 (5) , 833-839
- https://doi.org/10.1038/bjc.1992.369
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutantsPublished by Elsevier ,2003
- Intermittent high-dose tamoxifen as a potential modifier of multidrug resistanceEuropean Journal Of Cancer, 1992
- Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramineEuropean Journal of Cancer and Clinical Oncology, 1991
- Reversal of multidrug resistanceCancer Treatment Reviews, 1990
- Preclinical studies with toremifene as an antitumor agentBreast Cancer Research and Treatment, 1990
- Enhancement of adriamycin® cytotoxicity in a multidrug resistant Chinese hamster ovary (CHO) subline, CHO-Adrr, by toremifene and its modulation by alpha1 acid glycoproteinMaterials, 1990
- THE BIOCHEMISTRY OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCEAnnual Review of Biochemistry, 1989
- Inhibition of protein kinase C mediated signal transduction by tamoxifenBiochemical Pharmacology, 1986
- Genetic and biochemical characterization of multidrug resistancePharmacology & Therapeutics, 1985
- Cell Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian Cell LinesScience, 1983